Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Solid Biosciences Inc SLDB

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3... see more

Recent & Breaking News (NDAQ:SLDB)

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 10 hours ago

Solid Biosciences Joins the Russell 3000® Index

GlobeNewswire 18 hours ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 4, 2024

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

GlobeNewswire May 15, 2024

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire May 7, 2024

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 2, 2024

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 3, 2024

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

GlobeNewswire April 1, 2024

Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium

GlobeNewswire March 27, 2024

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

GlobeNewswire March 13, 2024

Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD

GlobeNewswire March 7, 2024

Solid Biosciences to Participate at Upcoming Investor Conferences

GlobeNewswire March 6, 2024

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

GlobeNewswire January 16, 2024

Solid Biosciences Announces $109 Million Private Placement

GlobeNewswire January 8, 2024

Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2024

Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003

GlobeNewswire December 7, 2023

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire November 22, 2023

Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

GlobeNewswire November 14, 2023

Solid Biosciences to Participate at Jefferies London Healthcare Conference

GlobeNewswire November 9, 2023

Solid Biosciences Provides Third Quarter Business Update and Financial Results

GlobeNewswire November 8, 2023